Decreased lipolysis and enhanced glycerol and glucose utilization by adipose tissue prior to development of obesity in monosodium glutamate (MSG) treated-rats.
OBJECTIVE
To determine the metabolic alterations that lead to the neonatal administration of monosodium glutamate (MSG), which results in arrested growth and obesity. ANIMALS AND DESIGN: Wistar rats were injected 5 times, every other day, with 4 g of MSG/kg b.w. or with hyperosmotic saline (controls), within the first 10 days of life, and were studied at the age of 30 days.


RESULTS
Body weight was lower, whereas adipocyte lipid content, cell diameter, surface area and volume were higher in MSG rats than in controls. Plasma glucose, insulin, NEFA, glycerol and triglyceride levels, and in vitro production of NEFA by lumbar fat pad pieces incubated under basal conditions or in the presence of epinephrine and epinephrine plus glucose in the media were lower in MSG than in control rats. In the same fat pad pieces, the conversion of 1-14C-glycerol into fatty acids was always enhanced and its conversion into glyceride glycerol was enhanced when incubations were carried out in the presence of epinephrine or glucose. Both the hormone sensitive lipase activity and mRNA expression were lower in adipose tissue from MSG rats. Besides, the number of insulin receptors, lipid synthesis from U14C glucose, 3H-2-deoxy D-glucose uptake and cellular GLUT4 translocation index were higher in adipocytes from MSG rats than from the controls.


CONCLUSIONS
It is proposed that an enhanced insulin sensitivity in 1 month old MSG rats is responsible for the decreased lipolytic activity and enhanced glucose uptake. In addition, the enhanced lipogenesis and glycerol reutilization seen in their adipose tissue, disturbs the normal balance between fat depots breakdown and accumulation in favor of the latter.
Dolnikoff
M
M
Department of Physiology, Federal University of São Paulo, Brazil.
Martín-Hidalgo
A
A
Machado
U F
UF
Lima
F B
FB
Herrera
E
E
D000273:Adipose Tissue / Q000187:drug effects* / Q000378:metabolism*; D000818:Animals; D000831:Animals, Newborn; D005947:Glucose / Q000378:metabolism*; D051275:Glucose Transporter Type 4; D005990:Glycerol / Q000378:metabolism*; D008066:Lipolysis / Q000187:drug effects; D008297:Male; D009004:Monosaccharide Transport Proteins / Q000378:metabolism; D009124:Muscle Proteins; D009765:Obesity / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D012970:Sodium Glutamate / Q000494:pharmacology*; D002787:Sterol Esterase / Q000378:metabolism
D051275:Glucose Transporter Type 4; D009004:Monosaccharide Transport Proteins; D009124:Muscle Proteins; C495694:Slc2a4 protein, rat; D002787:Sterol Esterase; D005947:Glucose; D005990:Glycerol; D012970:Sodium Glutamate